Nerviano Medical Sciences Srl has synthesized Werner syndrome ATP-dependent helicase (WRN; RECQ3; RECQL2) inhibitors reported to be useful for the treatment of cancer, diabetic nephropathy, organ transplant rejection, arthritis, fibrosis, inflammation, neurodegeneration and metabolic diseases.

Nerviano Medical Sciences Srl has identified cyclin-dependent kinase 11A (CDK11A) inhibitors reported to be useful for the treatment of cancer and immunological disorders.

Nerviano Medical Sciences Srl has synthesized substituted pyrrole carboxamides acting as cell division cycle 7-related protein kinase (CDC7) inhibitors reported to be useful for the treatment of cancer.

Merck KGaA has struck a collaboration and option-to-license deal with Nerviano Medical Sciences Srl centered around NMS-293, a next-generation PARP-1 inhibitor already in early clinical development for brain tumors. Merck is making a play for the poly (ADP-ribose) polymerase (PARP) inhibitor market, first opened up in December 2014 by Astrazeneca plc, when Lynparza (olaparib) was first approved in advanced ovarian cancer, going on to become a blockbuster through a partnership with Merck & Co Inc.